Adaptimmune Therapeutics (ADAP) Earnings Date & Reports

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

ADAP is expected to report earnings to rise 140.60% to -12 cents per share on May 15

Adaptimmune Therapeutics ADAP Stock Earnings Reports

Q1'25

Est.

$-0.12

Q4'24

Missed

by $0.02

Q3'24

Est.

$-0.01

Q2'24

Beat

by $0.09

Q1'24

Beat

by $0.12

The last earnings report on March 20 showed earnings per share of -5 cents, missing the estimate of -2 cents. With 432.06K shares outstanding, the current market capitalization sits at 70.30M.

View a ticker or compare two or three

Compare

ADAP